President and CEO, Takeda
Appears in 1 story
Publicly positioning zasocitinib as a future growth pillar
Psoriasis has been an injectable kingdom for years: shots that work great, pills that usually don’t. Takeda’s once-daily TYK2 pill zasocitinib just cleared pivotal Phase 3 topline hurdles—and by the next session investors responded, sending Takeda shares up as much as 4.3% in early Tokyo trading (a seven-month-high intraday jump).
Updated Dec 18, 2025
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
